Volume 29, Number 3—March 2023
Dispatch
Emergomyces pasteurianus in Man Returning to the United States from Liberia and Review of the Literature
Table 1
MIC/MEC (μg/mL)Antimicrobial susceptibility of antifungal agents for Emergomyces pasteurianus isolate from a patient returning to the United States from Liberia and reported cases from the literature*
Case (ref) | AMB | MICA | ANID | FLC | ITC | VOR | POS | ISA | 5-FC |
---|---|---|---|---|---|---|---|---|---|
This study |
0.25 |
0.03 |
<0.015 |
>64 |
0.06 |
0.25 |
0.25 |
1.0 |
>64 |
1 (8) |
0.031 |
0.031 |
0.5 |
>64 |
0.125 |
0.25 |
0.125 |
2.0 |
NA |
2 (9) |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
3 (4) |
1.0 |
0.05 |
NA |
2.0 |
0.125 |
0.25 |
0.125 |
NA |
NA |
4 (10) |
0.125 |
0.063 |
0.0031 |
>64 |
0.25 |
0.25 |
0.063 |
1.0 |
NA |
5 (11) |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
6 (5) |
0.031 |
<0.008 |
NA |
64 |
0.063 |
0.25 |
0.063 |
1.0 |
NA |
7 (5) |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
8 (12) |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
9 (13) |
1.0 |
0.5† |
NA |
4.0 |
0.125 |
0.25 |
0.125 |
NA |
NA |
10 (14) | NA | NA | NA | NA | NA | NA | NA | NA | NA |
*Values are MICs (μg/mL), except as indicated. 5-FC, 5-fluorocytosine; AMB, amphotericin B; ANID, anidulafungin; FLC, fluconazole; ISA, isavuconazole; ITC, itraconazole; MICA, micafungin; POS, posaconazole; ref, reference; VOR, voriconazole. †Caspofungin minimal effective concentration.
References
- Schwartz IS, Kenyon C, Feng P, Govender NP, Dukik K, Sigler L, et al. 50 years of Emmonsia disease in humans: the dramatic emergence of a cluster of novel fungal pathogens. PLoS Pathog. 2015;11:
e1005198 . DOIPubMedGoogle Scholar - Dukik K, Muñoz JF, Jiang Y, Feng P, Sigler L, et al. Novel taxa of thermally dimorphic systemic pathogens in the Ajellomycetaceae (Onygenales). 2018;60:296–309.
- Samaddar A, Sharma A. Emergomycosis, an emerging systemic mycosis in immunocompromised patients: current trends and future prospects. Front Med (Lausanne). 2021;8:
670731 . DOIPubMedGoogle Scholar - Dukik K, Al-Hatmi AMS, Curfs-Breuker I, Faro D, de Hoog S, Meis JF. Antifungal susceptibility of emerging dimorphic pathogens in the family Ajellomycetaceae. Antimicrob Agents Chemother. 2017;62:e01886–17.PubMedGoogle Scholar
- Maphanga TG, Britz E, Zulu TG, Mpembe RS, Naicker SD, Schwartz IS, et al. In vitro antifungal susceptibility of yeast and mold phases of isolates of dimorphic fungal pathogen Emergomyces africanus (formerly Emmonsia sp.) from HIV-infected South African patients. J Clin Microbiol. 2017;55:1812–20. DOIPubMedGoogle Scholar
Page created: January 12, 2023
Page updated: February 20, 2023
Page reviewed: February 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.